EUVIMEDEUVIMED entdecken
Open Access

Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia

Hope E DiTaranto, Astrela Moore, Rebecca Kendsersky, Jessica Zook, Elana Katz, Sarah H Evans, J Michael King

The Journal of Pediatric Pharmacology and Therapeutics · 2026-06 · 31 (3) · 372-379

DOI: 10.5863/jppt-25-00052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-06. Verfasst von Hope E DiTaranto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (HED, AM, RK, JZ), Children's Hospital of Philadelphia, Philadelphia, PA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Baclofen is used for hypertonia in infants despite limited dosing guidance. This study describes enteral baclofen prescribing in patients 12 months of age and younger. METHODS This single-center, retrospective review evaluated infants receiving enteral baclofen from January 2013 to December 2022. Regimen information, including dose, frequency, age, weight, and duration of treatment for up to 1 year following initiation, was assessed. Other outcomes included place in therapy, safety, and tolerability. RESULTS This study included 108 patients with 423 total regimens. At initiation, the median baclofen dose was 1.3 mg, corresponding to a weight-based dose (WBD) of 0.2 mg/kg, a total daily dose (TDD) of 3 mg, and a weight-based total daily dose (wTDD) of 0.5 mg/kg/day. Sixty-one patients (56.5%) received baclofen 3 times daily at initiation. The patients’ longest-tolerated regimen had a median dose of 2.8 mg, corresponding to a WBD of 0.4 mg/kg, a TDD of 9 mg, and a wTDD of 1.3 mg/kg/day. Hypoxemic-ischemic encephalopathy and brain injury were the most common etiologies of hypertonia. Baclofen was the first antispastic agent for 37 patients (34.3%). Twenty-four patients (22.2%) discontinued baclofen within 1 year. Four patients (3.7%) stopped baclofen due to adverse effects (sedation and emesis). CONCLUSIONS The median initiation dose of baclofen in infants was lower than the recommended dose for patients aged younger than 2 years, highlighting variability in practice. The baclofen regimens used in this study were safe and well-tolerated. These findings provide insight into baclofen prescribing for infants with hypertonia.

Schlagwörter

Stichwörter der Autor:innen

baclofenbrain injuriesbrain ischemiamuscle hypertoniamuscle spasticity

Autor:innen und Institutionen

  • Department of Pharmacy (HED, AM, RK, JZ), Children's Hospital of Philadelphia, Philadelphia, PA.
  • Division of Physical Medicine and Rehabilitation (EK, SHE, JMK), Children's Hospital of Philadelphia, Philadelphia, PA.

Zitieren

APA

DiTaranto, H. E., Moore, A., Kendsersky, R., Zook, J., Katz, E., Evans, S. H., & King, J. M. (2026). Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia. The Journal of Pediatric Pharmacology and Therapeutics, 31(3), 372-379. https://doi.org/10.5863/jppt-25-00052

Vancouver

DiTaranto HE, Moore A, Kendsersky R, Zook J, Katz E, Evans SH, et al. Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(3):372-379. doi:10.5863/jppt-25-00052

BibTeX
@article{DiTaranto2026,
  author = {DiTaranto, Hope E and Moore, Astrela and Kendsersky, Rebecca and Zook, Jessica and Katz, Elana and Evans, Sarah H and King, J Michael},
  title = {Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia},
  journal = {The Journal of Pediatric Pharmacology and Therapeutics},
  year = {2026},
  volume = {31},
  number = {3},
  pages = {372--379},
  doi = {10.5863/jppt-25-00052}
}
Kostenlos starten →